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Muscle diseases can constitute a large variety of both acquired and hereditary disorders.
Myopathies in systemic disease results from several different disease processes includ-
ing endocrine, inﬂammatory, paraneoplastic, infectious, drug- and toxin-induced, critical
illness myopathy, metabolic, and myopathies with other systemic disorders. Patients with
systemic myopathies often present acutely or sub acutely. On the other hand, familial
myopathies or dystrophies generally present in a chronic fashion with exceptions of meta-
bolic myopathies where symptoms on occasion can be precipitated acutely. Most of the
inﬂammatory myopathies can have a chance association with malignant lesions; the inci-
dence appears to be speciﬁcally increased only in patients with dermatomyositis. In dealing
with myopathies associated with systemic illnesses, the focus will be on the acquired
causes. Management is beyond the scope of this chapter. Prognosis is based upon the
underlying cause and, most of the time, carries a good prognosis. In order to approach a
patient with suspected myopathy from systemic disease, a stepwise approach is utilized.
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STEP 1: OVERVIEW AND UNDERSTANDING OF MYOPATHIES
IN SYSTEMIC ILLNESSES
Muscle diseases represent a wide variety of both acquired and
hereditary disorder. The underlying disease can involve muscles at
both structural and functional levels including metabolism as well
as muscle ion channel. The primary care physician is most likely to
be involved in the initial diagnosis of inﬂammatory myopathy and
of myopathy that results from systemic disease or toxic exposure
(Srinivasan and Amato, 2003; Jackson, 2008). Please see Table 1
for classiﬁcation of myopathies with systemic disorders.
ENDOCRINE MYOPATHIES
Overall, muscle fatigue is more common than true weakness. The
cause of weakness in these disorders is not well-deﬁned. It also
remains unclear that weakness results from disease of muscle as
opposed to another part of the motor unit. The serum CK level
is often normal (except in hypothyroidism). Nearly all endocrine
myopathies respond to treatment (Horak and Pourmand, 2000).
Thyroid disorders
Abnormalities of thyroid function can cause a wide array of mus-
cle disorders. This is very obvious from the important role of
thyroid hormones in regulating the metabolism of carbohydrates,
proteins, and lipids. In addition, thyroid hormones also stimulate
calorigenesis in muscle, increase muscle demand for vitamins, and
enhance muscle sensitivity to circulating catecholamines.
Hypothyroidism
Patients with hypothyroidism have frequent muscle complaints,
and proximal muscle weakness occurs in about one-third of them.
Muscle cramps, pain, and stiffness are common. Features of slow
muscle contraction and relaxation occur in 25% of patients; the
relaxation phase of muscle stretch reﬂexes is characteristically pro-
longed and best observed at the ankle or biceps brachii reﬂexes.
The serum CK level is often elevated (up to 10 times normal),
even when there is minimal clinical evidence of muscle disease.
Hoffman’s syndrome results in prominent muscle enlargement
and weakness with muscle stiffness (Horak and Pourmand, 2000;
Turker et al., 2008).
Hyperthyroidism
Patients who are thyrotoxic commonly have proximal muscle
weakness and atrophy on examination, but they rarely complain of
the deﬁcit. Muscle stretch reﬂexes are usually preserved and often
brisk. Bulbar, respiratory, and even esophageal muscles may occa-
sionally be affected, causing dysphagia, dysphonia, and aspiration.
Other neuromuscular disorders occur in association with hyper-
thyroidism, including hypokalemic periodic paralysis, myasthenia
gravis, and a progressive ocularmyopathy. SerumCK levels are not
elevated in thyrotoxic myopathy. The muscle biopsy reveals atro-
phy of muscle ﬁbers (Kung, 2007; Tsuda et al., 2008; Mansourian,
2010).
Hypoparathyroidism
An overt myopathy due to hypocalcemia rarely occurs. Neu-
romuscular symptoms are usually related to localized or gen-
eralized tetany. Serum CK levels may be increased secondary
to muscle damage from sustained tetany. Hyporeﬂexia or are-
ﬂexia is usually present and contrasts with the hyperreﬂexia in
hyperparathyroidism (Syriou et al., 2005).
Hyperparathyroidism
Proximal muscle weakness, muscle wasting, and brisk muscle
stretch reﬂexes. Serum CK levels are usually normal or slightly
elevated. Serum calcium and phosphorus levels show no cor-
relation with the clinical neuromuscular manifestations. Muscle
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Table 1 | Classification of myopathies with systemic disorders.
Endocrine myopathies
Inﬂammatory myopathies
Paraneoplastic myopathy
Myopathy from infectious disease
Drugs- and toxin-induced myopathies
Critical illness myopathy
Metabolic myopathies
biopsy reveals only varying degrees of atrophy without mus-
cle ﬁber degeneration (Horak and Pourmand, 2000; Habib and
Camacho, 2010).
Adrenal disorders
Can lead to variety of problems from either excess or deﬁciency.
Glucocorticoid excess, either endogenous or exogenous, produces
various degrees of proximal limb weakness in the form of myopa-
thy. Steroid myopathy is the most commonly diagnosed endocrine
muscle disease. Muscle wasting may be striking. A cushingoid
appearance usually accompanies clinical signs of myopathy. Mus-
cle biopsy demonstrates muscle type II ﬁber atrophy (Kanda et al.,
2001).
Adrenal insufﬁciency commonly causes muscle fatigue. The
degree of weakness may be difﬁcult to assess but is typically mild.
In primary hyperaldosteronism (Conn’s syndrome), neuromus-
cular complications with proximal muscle weakness are due to
potassium depletion. Serum CK levels may be elevated, and a
muscle biopsy may demonstrate degenerating ﬁbers, some with
vacuoles. These changes relate to hypokalemia and are not a direct
effect of aldosterone on skeletal muscle (Horak and Pourmand,
2000; Cicala and Mantero, 2010).
Pituitary disorders
Patients with acromegaly usually have mild proximal weak-
ness without muscle atrophy. Muscles often appear enlarged but
exhibit decreased force generation. The duration of acromegaly,
rather than the serum growth hormone levels, correlates with the
degree of myopathy. A multitude of treatment options exist for
patients with acromegaly including surgery, radiotherapy, somato-
statin analogs, dopamine agonists, and growth hormone recep-
tor antagonists (Horak and Pourmand, 2000; Del Porto et al.,
2011).
Diabetes mellitus
Neuromuscular complications of diabetes mellitus are most often
related to neuropathy – cranial, peripheral nerve, or lumbosacral
plexus. The only notable myopathy of diabetes mellitus is ischemic
infarction of thigh muscles. This condition occurs in patients with
poorly controlled diabetes and presents with abrupt onset of pain,
tenderness, and edema of one thigh. The area of muscle infarction
is hard and indurated. The muscles most often affected include
the vastus lateralis, thigh adductors, and biceps femoris. CT or
MRI can demonstrate focal abnormalities in the affected muscle.
Diagnosis by imaging is preferable to muscle biopsy, if possible
(Yildirim Donmez and Feldman, 2008).
INFLAMMATORY MYOPATHIES: ASSOCIATION WITH MALIGNANCIES
Most of the inﬂammatory myopathies can have a chance associ-
ation with malignant lesions. The incidence of malignant condi-
tions appears to be speciﬁcally increased only in patients with Der-
matomyositis, and not in Polymyositis or Inclusion body myositis.
The more common tumors associated with dermatomyositis are
ovarian cancer, breast cancer, melanoma, colon cancer, and non-
Hodgkin’s lymphoma. The extent of the search that should be
conducted for an occult neoplasm in adults with dermatomyositis
depends on the clinical circumstances. Tumors in these patients
are usually uncovered by abnormal ﬁndings in the medical his-
tory and physical examination. The weight of evidence argues
against performing expensive, invasive, and non-directed tumor
searches. Nishigori et al. (2009) have emphasized higher malig-
nancy in patients with vesiculobullous dermatomyositis. Vigilance
is required with a complete annual examination with pelvic,
breast (mammogram, if indicated), and rectal examinations (with
colonoscopy according to age and family history); urine analy-
sis; complete blood count; complete metabolic proﬁle; chest x-ray
ﬁlm should be adequate in most cases. In Asians, nasopharyn-
geal cancer is common, and a careful examination of ears, nose,
and throat is indicated (Kawachi et al., 2008; Nishigori et al.,
2009).
Inﬂammatory myopathies: overlap syndromes
The association of inﬂammatory myopathies with connective
tissues disease deﬁnes the overlap syndromes. Inﬂammatory
myopathies do not commonly occur as a part of well-deﬁned
connective tissue disorders like SLE or RA but can be a part of
overlap syndromes such as mixed connective tissue disease. A
well-characterized overlap syndrome occurs in patients with der-
matomyositis who also have manifestations of systemic sclerosis
or mixed connective tissue disease including: sclerotic thickening
of the dermis, contractures, esophageal hypomotility, microan-
giopathy, and calcium deposits. Blood vessels in muscles can be
involved as part of a systemic vasculitis. Patients with the over-
lap syndrome of dermatomyositis and systemic sclerosis may have
a speciﬁc antinuclear antibody, the anti-PM/Scl, directed against
a nucleolar-protein complex. The treatment for inﬂammatory
myopathies is similar to that for polymyositis anddermatomyositis
(Kawachi et al., 2008; Nishigori et al., 2009).
PARANEOPLASTIC MYOPATHY
Patientswith paraneoplastic syndromedevelopmyalgias and rapid
progression of weakness involving the extremities, pharyngeal
and respiratory muscles, often resulting in death. Serum muscle
enzymes are elevated, and muscle biopsy shows extensive necrosis
with minimal or absent inﬂammation and sometimes deposits of
complement. The disorder occurs as a paraneoplastic manifesta-
tion of a variety of cancers including small cell lung cancer and
cancer of the gastrointestinal tract, breast, kidney, and prostate,
among others. Glucocorticoids or treatment of the underlying
tumor rarely control the disorder (Ramchandren and Dalmau,
2005; Antoine and Camdessanché, 2007; Kawachi et al., 2008).
Apostolidis et al. (2009) have reported a rare case with der-
matomyositis and non-hepatitis-associated advanced hepatocel-
lular carcinoma with metastases. The dermatomyositis responded
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well to treatment with prednisolone and azathioprine (Apostolidis
et al., 2009).
MYOPATHY FROM INFECTIOUS DISEASE
When acute weakness is associated with painful muscle cramps,
rhabdomyolysis, and myoglobinuria, it may be due to metabolic
disorders or infectious illness. Among the infectious etiologies –
viral infections aremore common. Inﬂuenza virusmyositis is char-
acterized by severe pain, tenderness and swelling, predominantly
affecting the calves and to some extent may involve the thighs also.
Myalgia is the most common symptoms and usually begins a week
after the onset of inﬂuenza infections and can last for another 2–
3weeks. The disorder is usually self limited but severe cases are
at risk for myoglobinuria and renal failure. Epidemics of Cox-
sackie virus group B can lead to self-limited acute inﬂammatory
myopathy (Kumar et al., 2011).
The clinical and histopathologic features of HIV-associated
myopathy are indistinguishable from those of idiopathic
polymyositis, and the condition is often referred to as HIV
polymyositis. It may occur at any stage of HIV infection, but is
rarely the ﬁrst clinical presentation of HIV. HIV polymyositis
may range in severity from an asymptomatic elevation in creatine
kinase levels to a subacute syndrome characterized by proximal
weakness.HIV-associated inclusion bodymyositis aswell as nema-
line rod myopathy has been described as well (Dalakas et al.,
2007; de Sanctis et al., 2008). Characteristics of polymyositis in
HIV versus non-HIV infected patients have been compared. It
has been observed that HIV polymyositis is treatable but may
present with less than twofold CK elevation above normal (Heck-
mann et al., 2010). The treatment of HIV polymyositis is similar
to that of idiopathic polymyositis and includes glucocorticoids,
azathioprine, cyclophosphamide, and intravenous immunoglob-
ulin (IVIgG). Immunosuppressants must be used cautiously in
HIV patients as prolonged administration of oral glucocorti-
coids has been associated with an increased risk of opportunistic
infections, and pulse intravenous glucocorticoids may be a more
attractive alternative (Tien-Auh Chan et al., 2007; Kung et al.,
2011).
Several animal parasites, such as protozoa (toxoplasma, try-
panosoma), cestodes (cysticerci), and nematodes (trichinae), may
produce a focal or diffuse inﬂammatory myopathy known as par-
asitic polymyositis. Kung et al. (2011) have recently reported a
case of AIDS and toxoplasmosis presenting initially with myelitis
in the absence of encephalitis and subsequently progressing to
myositis despite antiparasitic treatment. American trypanosomi-
asis (Chagas disease) is caused by Trypanosoma cruzi and can
cause inﬂammatory myopathy as well superimposed neuropa-
thy. African trypanosomiasis on the other hand can manifest
with myocarditis, polymyositis, and encephalopathy. Cysticerco-
sis results from infection by Cysticercus cellulosae, the larval form
of the pork tapewormTaenia solium. The encysted parasite may be
found in the skeletal and heart muscle, as well as the eye and brain.
The clinical features may vary based upon the number and loca-
tionof the cysts. Trichinosis is causedby larva ofTrichinella spiralis,
and is associated with fever, myalgia, proximal muscle weakness,
periorbital, and facial edema. Trichinosis on occasion may mimic
mild dermatomyositis.
Staphylococcus aureus, Yersinia, Streptococcus, or other anaero-
bic bacteria like clostridia may produce a suppurative myositis,
known as topical polymyositis, or pyomyositis. Pyomyositis, pre-
viously rare in the west, is now occasionally seen in AIDS patients.
Other bacteria, such as Borrelia burgdorferi (Lyme disease) and
Legionella pneumophila (Legionnaires’ disease) may infrequently
cause myositis (Crum-Cianﬂone, 2008; Al-Najar et al., 2010; Kung
et al., 2011).
Fungal myositis is uncommon and may be seen in immuno-
compromisedpatients (e.g.,AIDSorwithmalignancies). Sporotri-
chosis, histoplasmosis, mucormycosis, cryptococcosis, and can-
didiasis are all associated with myositis. Mucormycosis can spread
to the orbit producing ophthalmoplegia, proptosis, and eyelid
edema. Sporotrichosis and histoplasmosis can involve a single
muscle or a group of muscles with abscess formation. Patients
with disseminated candidiasis can develop papular rash, myalgia,
and diffuse muscle weakness (Al-Najar et al., 2010).
DRUGS- AND TOXIN-INDUCED MYOPATHIES
Drug-induced myopathies are relatively uncommon in the clinical
practice with the exception of those caused by the cholesterol-
lowering agents and glucocorticoids. The knowledge of these
myopathies remains critical since timely diagnosis allows for
recovery (Kuncl, 2009; Abd and Jacobson, 2011).
Myopathy from lipid-lowering agents
All classes of lipid-lowering agents have been implicated in mus-
cle toxicity including ﬁbrates (cloﬁbrate, gemﬁbrozil), HMG-CoA
reductase inhibitors (statins), and niacin (nicotinic acid). Myalgia,
malaise, and muscle tenderness are the most common manifesta-
tions. Muscle pain may be related to exercise. Patients may exhibit
proximal weakness. Varying degrees of muscle necrosis are seen,
and in severe reactions there are rhabdomyolysis and myoglobin-
uria. Toxicity is dose and time related, secondary to initiation of
HMG-CoA reductase inhibitor (Kuncl, 2009). Concomitant use
of statins with ﬁbrates and cyclosporine is more likely to cause
adverse reactions than use of one agent alone. Elevated serum CK
is an important indication of toxicity. Muscle weakness is accom-
panied by a myopathic EMG, and muscle necrosis is observed
by muscle biopsy (Findling et al., 2008; Radcliffe and Campbell,
2008). Myopathic reactions are indications for stopping the drug
and patients improvewith drug cessation.Most recently, switching
to lower dose or even non-daily doses of long acting stating has
been recommended as an alternate to discontinuing statins (Abd
and Jacobson, 2011).
Glucocorticoid-related myopathies
Glucocorticoid myopathy is the most common type of drug-
induced myopathy. It occurs with chronic treatment with prox-
imal weakness accompanied by cushingoid manifestations. The
chronic use of prednisone at a daily dose of ≥ 30mg/day is most
often associatedwith toxicity. Patients takingﬂuorinated glucocor-
ticoids (triamcinolone, betamethasone, dexamethasone) appear
to be especially high risk for myopathy. Patients receiving high-
dose, intravenous glucocorticoids for status asthmaticus, chronic
obstructive pulmonary disease, or other indications may develop
severe generalized weakness. In chronic steroid myopathy the
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serum CK is usually normal but serum potassium may be low.
In acute cases with quadriplegic myopathy, the muscle biopsy is
abnormal and shows a distinctive loss of thick ﬁlaments (Myosin).
The muscle biopsy in chronic cases shows preferential type 2 mus-
cle ﬁber atrophy. EMG is usually normal as it measures type I ﬁber
function only. Given the treatment is primarily reduction or dis-
continuation of steroids, it remains very essential to distinguish
myopathy from glucocorticoid versus muscle inﬂammatory dis-
ease. In acute quadriplegic myopathy, recovery is slow and patients
require supportive care and rehabilitation (Horak and Pourmand,
2000; Pereira and Freire de Carvalho, 2011).
Alcohol and drugs of abuse related myopathies
Myotoxicity is a potential consequence of addiction to alcohol and
illicit drugs. Ethanol is one of the most commonly abused sub-
stances with potential to damage muscle. Direct muscle damage
is less certain, since toxicity usually occurs in the setting of poor
nutrition and possible contributing factors such as hypokalemia
and hypophosphatemia. Acute muscle weakness with myoglobin-
uria may occur with prolonged severe hypokalemia, hypophos-
phatemia, or hypomagnesemia that is seen in chronic alcoholics
and patients on nasogastric suction receiving parenteral hyperal-
imentation. Low vitamin D levels are related to muscle atrophy
while changes in muscle antioxidant enzymes may play a role
in alcoholic myopathy. Chronic alcoholic may develop painful
myopathy with myoglobinuria after a bout of heavy drinking or
present with a painless, acute hypokalemic myopathy that is com-
pletely reversible with replacement therapy (Noordzij et al., 2007;
González-Reimers et al., 2010).
Drugs of abuse and focal myopathies
Other potential toxins include cocaine, heroin, and amphet-
amines. Coma and seizures, causing rhabdomyolysis, myoglo-
binuria, and renal failure are some complications (Gutiérrez-
Gutiérrez, 2010). Focal myopathies from self-administration of
meperidine, heroin, and pentazocine can cause pain, swelling,
muscle necrosis, and hemorrhage. The cause is multifactorial
including needle trauma, direct toxicity of the drug or vehicle,
infection, non-granulomatous or granulomatous disorders such
as sarcoidosis. When severe, there is skin induration and contrac-
tures with replacement of muscle by connective tissue can occur.
Elevated serum CK is characteristic and peak value for blood myo-
globin might be a good indicator of rhabdomyolysis induced acute
renal failure. EMG is signiﬁcant for myopathic ﬁndings and mus-
cle biopsy reveals focal areas of necrosis. In focal myositis, ESR and
CK are always within normal range. Histologically, hypertrophy of
muscle ﬁbers and internalization of nuclei are pronounced in focal
myositis, but not in polymyositis. Focal myositis is self limited and
usually regresses spontaneously (Chawla et al., 2005). Treatment
is focused on rhabdomyolysis which require adequate hydration
to reduce serum myoglobin and protection of renal function. In
all of these conditions, counseling is essential to limit drug abuse
(Streichenberger et al., 2004; Chawla et al., 2005; O’Connor and
McMahon, 2008; Brancaccio et al., 2010; Kasaoka et al., 2010).
Other drug-induced myopathies
d-Penicillamine and procainamide may produce a true
myositis resembling polymyositis. In 1989 an epidemic of
eosinophilia–myalgia syndrome (dermatomyositis like illness) in
the United States was caused by l-tryptophan, a contaminant in
the product from one manufacturer. The incidence of this inﬂam-
matory muscle disease is about 1% (Silver et al., 1992; Klopstock,
2008; Rothschild, 2010). Myasthenia gravis is also induced by d-
penicillamine, with a higher incidence estimated at 7%. These
disorders resolve with drug withdrawal, although immunosup-
pressive therapy may be required in severe cases. Reports of other
drugs causing an inﬂammatory myopathy include cimetidine,
phenytoin, procainamide, and propylthiouracil. In most cases, a
cause-and-effect relationship is uncertain.
Certain drugs produce painless, largely proximal,muscle weak-
ness (please see Table 2). These drugs include the amphophilic
cationic drugs (amiodarone, chloroquine, hydroxychloroquine)
and antimicrotubular drugs (colchicine). Muscle biopsy can be
useful in the identiﬁcation of toxicity since autophagic vacuoles are
prominent pathologic features of these toxins (Klopstock, 2008;
Cantarini et al., 2010; Rothschild, 2010).
A myopathy similar to HIV polymyositis can be seen in patients
following prolonged treatment with the Zidovudine (AZT). The
toxic side effect of the drug is dose-dependent and is related to
its ability to interfere with the function of mitochondrial poly-
merases. The complication occurs in about one ﬁfth of patients
treated with doses of 1200mg/day for 6months. It is usually
Table 2 | Drugs induced toxic myopathies.
RHABDOMYOLYSIS AND MYOGLOBINURIA
Cholesterol-lowering drugs
Alcohol
Amphetamine
Heroin
Cocaine
e-Aminocaproic acid
Pentazocine
Phencyclidine
Toluene
INFLAMMATORY
D-Penicillamine
Procainamide
L-Tryptophan
Cimetidine
Levodopa
NON-INFLAMMATORY
Cholesterol-lowering agents
Steroids (associated with myosin loss)
Non-depolarizing neuromuscular blocking agents (associated with
myosin loss)
Chloroquine
Colchicine
Emetine
e-Aminocaproic acid
Labetalol
Cyclosporine
Isoretinoic acid
Vincristine
Alcohol
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reversible following discontinuation of the drug. Patients present
with progressive proximalweakness andprofoundmusclewasting,
often with muscle pain. Serum levels of CK are usually elevated,
and EMG shows non-speciﬁc myopathic changes. Muscle biopsy
reveals the histological hallmark of red ragged ﬁbers. The intro-
duction of protease inhibitors for treatment of HIV infection has
led to lower doses of zidovudine therapy and a decreased incidence
of myopathy (Scruggs and Dirks Naylor, 2008).
CRITICAL ILLNESS MYOPATHY
An acute myopathy affecting critically ill patients has been identi-
ﬁed by different terms; including acute quadriplegic myopathy or
critical illness myopathy (CIM). Unlike inﬂammatory myopathies,
myalgias are less commonly seen in CIM. Patients may receive
non-depolarizing neuromuscular blocking agents such as pan-
curonium, with or without glucocorticoids, may cause the acute
CIM. The clinical features are identical to acute quadriplegic
myopathy secondary to glucocorticoids. Major criteria include
a critical illness (sepsis, multiple organ failure), difﬁculties with
ventilator weaning, and possible limb weakness (Chawla, 2007;
Chawla and Gruener, 2010; Fernández-Lorente et al., 2010). CIM
may appear in various forms including thick ﬁlament myopathy,
acute necrotizing myopathym, or cachectic myopathy.
Thick ﬁlament myopathy is mainly observed in patients with
severe asthma often requiring ventilator support, high-dose corti-
costeroids, or neuromuscular blocking agents. SerumCK levels are
mildly elevated. Muscle biopsy shows destruction of thick myosin
ﬁlaments. Acute Necrotizing Myopathy is often precipitated by
multiple etiologies causing myoglobinuria. Serum CK levels are
markedly elevated. There is myoglobulinuria. Electrophysiologi-
cal studies demonstrate a severe myopathy. Muscle biopsies show
widespread necrosis of muscle ﬁbers. Cachectic Myopathy is also
known as disuse atrophy, it is responsible for marked wasting
and weakness of muscles. Laboratory studies are generally non-
speciﬁc. Muscle biopsy may show type 2 ﬁber atrophy. Cachectic
myopathy remains a diagnosis of exclusion.
Muscle biopsy is occasionally indicated for exact treatment
as well as prognosis in order to differentiate CIM from other
myopathies or from critical illness polyneuropathy. Management
of CIM requires avoiding corticosteroids and neuromuscular
blocking agents or use the lowest possible dosages, and only for
a short period of time. Prognosis is good with full recovery in
mild to moderate cases. In severe cases, recovery may be longer or
incomplete. Severe cases especially with necrotizing myopathy are
associated with a high mortality rate (Chawla and Gruener, 2010).
METABOLIC MYOPATHIES
Evaluation of patients with metabolic causes of muscle weakness
remains a challenge due to frequent lack of clinical symptoms.
Typical manifestations include exercise induced myalgias, exercise
intolerance, and cramps. Myopathies are caused by either excess
or deﬁciencies of some of these minerals including potassium,
calcium, phosphorous, magnesium, and vitamin D (Volpi et al.,
2011).
Metabolic myopathies: vitamin D deﬁciency
Vitamin D deﬁciency can occur from decreased intake, decreased
absorption, or impaired vitamin D metabolism (as occurs in renal
disease). Clinical manifestations include ataxic neuropathy due
to loss of proprioception and myopathy with proximal weakness.
Pain reﬂects the underlying bone disease (osteomalacia). Progres-
sive external ophthalmoplegia is a distinctive ﬁnding. It has not
been established that deﬁciency of other vitamins causes a myopa-
thy. Screening for vitamin D deﬁciency is essential as one of the
treatable causes of acquired myopathies (Prabhala et al., 2000;
Noordzij et al., 2007; Al-Said et al., 2009).
Metabolic myopathies: potassium and sodium related
Hypokalemia often causes proximal or generalized weakness that
is usually painless.With acute hypokalemic paralysis, serumpotas-
sium is well below 3.0mEq/L;weakness improves within 1–2 h and
resolves over several hours or days with potassium replacement.
If hypokalemia has been severe or associated with alcoholism, an
acute necrotizing myopathy with rhabdomyolysis and renal fail-
ure may result, which improves partially or completely over days
to weeks (Kotsaftis et al., 2009).
Hyperkalemia has severe and acute effects on both skeletal and
cardiac muscle, causing rapidly ascending quadriparesis, frequent
respiratory failure, and cardiac arrest. Serum potassium is usu-
ally> 7.5mEq/L. CK andmuscle biopsy are usually normal. Skele-
tal muscle weakness usually resolves within hours, even if serum
potassium has not changed. The common presence of paresthesias
and Chvostek’s signs suggests that hyperkalemia causes weakness
more through its effects on nerve than muscle (Adeniyi et al.,
2004).
Hypernatremia is rare but known to cause proximal muscle
weakness. Serum CK and sodium level are elevated with myo-
genic changes on the EMG study. Muscle weakness improves while
the hypernatremia is getting corrected. The pathophysiology is
likely due to depletion of the intramuscular energy stores from an
overworking Na–K pump to correct the intracellular electrolyte
imbalance (Hiromatsu et al., 1994).
Metabolic myopathies: calcium and phosphorous related
Abnormalities of calcium and phosphorus homeostasis and bone
metabolism in chronic renal failure result froma reduction in 1,25-
dihydroxyvitamin D, leading to decreased intestinal absorption of
calcium.
Hypocalcemia causes paresthesias and motor dysfunction from
tetany more than weakness with presence of Chvostek’s and
Trousseau’s signs; thus its symptoms and signs are better explained
by spontaneous peripheral nerve activity than by myopathy.
Hypercalcemia causes weakness with hyperreﬂexia, so this may
relate more to central nervous system effects than those on muscle.
Severe hypophosphatemia (serum phosphate less than
0.4mM/L) causes acute and severe areﬂexic weakness with rhab-
domyolysis. Because mild hypophosphatemia can be caused
by hyperventilation, only serum phosphorus levels less than
1.0mM/L should be considered as severe enough to cause weak-
ness or rhabdomyolysis (Amanzadeh and Reilly, 2006; Assadi,
2010).
The clinical picture of the myopathy of chronic renal failure is
identical to that of primary hyperparathyroidism and osteomala-
cia. There is proximal limb weakness with bone pain. Gangrenous
calciﬁcation, extensive skin necrosis, painful myopathy, and even
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myoglobinuria may occur (Srinivasan and Amato, 2003; Adeniyi
et al., 2004; Ning et al., 2009).
Metabolic myopathies: magnesium related
Hypomagnesemia is often associated with hypocalcemia and may
contribute to signs of tetany with weakness.
Hypermagnesemia is rarely encountered and usually is due
to exogenous administration of magnesium; if serum magne-
sium levels exceed 9.0mEq/L, severe generalized weakness with
respiratory failure usually develops (Adeniyi et al., 2004).
Myopathies in other systemic illness
Systemic illnesses such as chronic respiratory, cardiac, or hepatic
failure are frequently associated with severe muscle wasting and
complaints of weakness. Fatigue is usually amore signiﬁcant prob-
lem than weakness,which is typically mild (Srinivasan andAmato,
2003; Adeniyi et al., 2004; Ning et al., 2009).
STEP 2: CLINICAL APPROACH TO A PATIENT WITH MUSCLE
WEAKNESS
A successful clinical approach to a patient with a suspectedmyopa-
thy is based on a thorough medical history and neurological
examination (Srinivasan andAmato,2003; Jackson,2008;Weis and
Nolte, 2009; Selcen, 2011). The following systemic symptoms and
signs are extremely helpful in narrowing the differential diagnosis.
• History and physical examination are critical components to
appropriate diagnosis in any patient. It is a true saying – eyes
cannot see those things if brain doesn’t know what to look for.
Therefore, it remains essential to start knowing the pattern of
the disease while establishing your differential diagnosis. Please
see Table 3 for symptoms and signs associated with systemic
myopathies.
• Neurological History should include at the least the following
aspects:
◦ Fatigue is a very non-speciﬁc complaint. Many patients who
complain of diffuse global weakness or fatigue do not have a
disorder of muscle, particularly if the neurological examina-
tion is normal. On the other hand, abnormal fatigability after
exercise can result from certain metabolic and mitochondrial
myopathies in addition to neuromuscular junction disorders.
In addition, duration and intensity of exercise which precipi-
tates the fatigue is important (DiMauro, 2010; Schwager et al.,
2010).
Table 3 | Symptoms and signs associated with systemic myopathies.
Symptoms Signs
NEGATIVE
Weakness Muscle atrophy
Fatigue
POSITIVE
Myalgias Contractures
Cramps Hypertrophy
Myoglobinuria
◦ Myalgias are episodic in metabolic myopathies or persistent
in various inﬂammatory muscle disorders (Table 4 lists mus-
cle disorders with associated myalgias). Cramps are usually
benign and can occur with multiple conditions like dehydra-
tion, hyponatremia, azotemia, myxedema, etc. Contractures
differ from cramps in that they usually last longer and are
electrically silentwithneedle electromyography examination.
Myoglobinuria is caused by the excessive release of myoglobin
from muscle during periods of muscle destruction (rhab-
domyolysis). Severe myoglobinuria (Table 5 lists acquired
causes of myoglobinuria) can result in renal failure due to
acute tubular necrosis. Patients generally complain of coke-
colored or red urine during or after the exercise. Recurrent
myoglobinuria is usually due to an underlying metabolic
myopathy, whereas isolated episodes can occur in several
conditions like rigorous exercise, infections, drugs and tox-
ins, inﬂammatory myopathies, and malignant hyperthermia
(Cervellin et al., 2010).
◦ Temporal evolutions of symptoms help you to narrow down
your differential diagnosis. Know if the symptom presenta-
tion is acute, sub acute, or chronic, whether the symptoms
are constant or episodic, and if they progressive or non-
progressive. Identifying the age that symptoms began can
provide crucial information leading to the correct diagno-
sis (please see Table 6 for age of onset and the diagnosis of
myopathy). Myopathies related to systemic diseases generally
present with either constant weakness unlike episodic periods
of weaknesswith normal strength interictally (periodic paral-
ysis, metabolic myopathies due to certain glycolytic pathway
disorders). Ask for common precipitating factors including any
relationship with exercise, any association with high fever or
exposure to cold, any Critical Illness, and ICU stay, exposure
to drugs or toxin or any correlation with carbohydrate meal
(Srinivasan and Amato, 2003; Jackson, 2008).
• Neuromuscular Examination should look into and focus on the
following aspects:
◦ Start with identiﬁcation of the pattern of weakness. Look for
if symmetrical or asymmetrical, whether the involvement of
Table 4 | Muscle disorders associated with myalgias.
Infectious myositis (especially viral)
Inﬂammatory myopathies (polymyositis, dermatomyositis)
Drug-induced myopathies (lovastatin, chloroquine)
Endocrine (e.g., Hypothyroid myopathy)
Table 5 | Acquired causes of myoglobinuria.
Prolonged, intensive exercise
Prolonged fever
Viral and bacterial infections
Drugs and toxins (especially alcohol)
Neuroleptic malignant syndrome
Heat stroke
Crush injuries
Inﬂammatory myopathies
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Table 6 | Differential diagnosis of systemic myopathy based on age of
onset.
Myopathies presenting at birth
None as systemic causes; mainly hereditary
Myopathies presenting in childhood
Inﬂammatory myopathies – dermatomyositis, polymyositis (rarely)
Infectious myopathies
Endocrine and metabolic disorders – hypokalemia, hypocalcemia, hypercal-
cemia
Myopathies presenting in adulthood
Inﬂammatory myopathies – polymyositis, dermatomyositis, inclusion body
myositis, viral (HIV)
Infectious myopathies
Endocrine myopathies – thyroid, parathyroid, adrenal, pituitary disorders
Toxic myopathies – alcohol, corticosteroids, narcotics, colchicines, chloro-
quine
Critical illness myopathy
Metabolic myopathies
Paraneoplastic myopathy
muscles is proximal> distal, distal> proximal or equal in
both proximal and distal muscles. Don’t forget the involve-
ment of cranial nerves with ocular, pharyngeal, and facial.
Most common pattern of weakness in myopathies is sym-
metric, proximal> distal weakness in the upper and lower
extremities. Neck muscles are frequently involved. Differ-
ential diagnosis of proximal acquired weakness consists of
inﬂammatory myopathy, including polymyositis and der-
matomyositis, endocrine myopathy, toxic- or drug-induced
as well as CIM (Jackson, 2008; Distad et al., 2011).
◦ Proximal muscle weakness is associated with difﬁculty climb-
ing stairs, arising from a chair, combing hair or lifting objects
overhead. On the other hand, distal muscle weakness can lead
to difﬁculty opening or closing jars, foot drop. Always make
an attempt to look for cranial muscle weakness with ptosis,
facial weakness, dysphagia, or any dysarthria.
◦ Look for other associated signs including myotonia, paramy-
otonia, and muscle hypertrophy to exclude other non-systemic
causes of muscle weakness. Myotonia can be elicited by percus-
sion,occurs by impaired relaxationof muscle due to repetitive
depolarization of the muscle. Both myotonia and paramy-
otonia are worsened by exposure to cold. Myotonia improves
with repeated exercise and paramyotonia is worsened by exer-
cise. Also look for muscle hypertrophy which is seen with
hypothyroid myopathy, amyloidosis, sarcoidosis, neoplastic,
and inﬂammatory process.
◦ Please keep in consideration other system involvement: cardiac
disease remains as the most important cause of mortal-
ity. Therefore identifying conditions with associated cardiac
disease is mandatory in patient care. The clinical presen-
tation of cardiac disease in these patients is either con-
gestive heart failure or cardiac arrhythmias. Most are seen
with genetic rather than acquired cause’s, e.g., polymyosi-
tis. Presence of hepatomegaly, optic atrophy, and/or pig-
mentary retinopathy should lead the examiner to explore
causes of myopathies other than systemic disorders. The
presence of a rash is extremely helpful in conﬁrming the
diagnosis of dermatomyositis and vasculitis. Family history
is important to know and is actually important for genetic
causes and less likely for myopathies with systemic illnesses
(Jackson, 2008).
• Establishment of Differential Diagnosis based upon the pattern
of disease process:
◦ Differential diagnosis remains a very crucial step in coming
to the diagnosis and ultimate decisive process in the man-
agement of your patient. Understanding of the prior steps
is essential as how to approach your next patient with mus-
cle weakness and helps you identify a pattern of the disease
(Srinivasan and Amato, 2003; Weis and Nolte, 2009; Marie,
2011; Selcen, 2011). The differential diagnosis of any sys-
temic myopathy (please also see Table 1) should include the
following:
• Endocrine myopathies
• Inﬂammatory myopathies
• Paraneoplastic myopathy
• Infectious myopathies
• Drug- and toxin-induced myopathies
• Critical illness myopathy
• Metabolic and myopathies with other systemic disorders
STEP 3: UTILITY OF LABORATORY TESTING INCLUDING
MUSCLE BIOPSY
Once you have established an appropriate differential diagnosis,
the next step is to order the necessary testing’s. This is similar
to establishing a hypothesis and ruling in and ruling out your
diagnosis. Cost effective tests can be ordered by the priority of
differential diagnosis. Commonly used tests in a patient with sus-
pected myopathy include Blood : CK, Aldolase, SGOT, SGPT, and
LDH,Neurophysiology : EMG/NCS,Muscle Biopsy, andGenetic test-
ing. Genetic testing is not relevant for acquired systemic causes of
muscle disorders.
The blood test of higher yield is CK although SGOT, SGPT,
and LDH should also be tested. CK elevation can occur with or
without muscle weakness, In addition, CK elevation is seen with
certain medications and occasion without any known cause. Mea-
surement of aldolase may be helpful in patient with mild weakness
and normal CK’s (Nozaki and Pestronk, 2009).
DIFFERENTIAL DIAGNOSIS OF CK ELEVATION WITH WEAKNESS
• CK elevation can occur with weakness in myopathies of Inﬂam-
matory,metabolic, endocrine, drug- or toxin-induced, and viral
illnesses. In addition, CK elevation can occur with weakness in
other disorders including channelopathies, neuropathies (like
GBS, CIDP), and motor neuron disease. Metabolic myopathy
should be suspected in patients with sole exercise-related mus-
cle pain and CK seven times higher than the normal (Filosto
et al., 2007). Please see Table 7 for differential diagnosis of CK
elevation.
DIFFERENTIAL DIAGNOSIS OF CK ELEVATION WITHOUT WEAKNESS
• CK elevation is occasionally encountered in patients with-
out any clinical weakness or any other expression of a
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neuromuscular disorder. It is still unresolved whether extensive
investigations and speciﬁcally a muscle biopsy should be per-
formed in clinically normal individuals with elevated CK levels.
CK elevation without weakness can occur in strenuous exercise,
after EMG studies, trauma including surgeries, intramuscular
injections, carrier state (dystrophinopathy), “Idiopathic Hyper-
CKemia,” metabolic and congenital myopathy, medications as
well as African American’s. Please see Table 8 for effect of race
and gender on CK measurement. Abnormal muscle biopsies
were found in over half the patients with asymptomatic or min-
imally symptomatic hyperCKemia (Johnson et al., 1971; Joy and
Oh, 1989; Dabby et al., 2006).
MEDICATIONS AND CK ELEVATIONS
• In addition, note should be made of certain medications ele-
vating CK’s. These medications are Lipid-lowering drugs like
HMG-CoA reductase inhibitors (Statins), Fibric acid deriva-
tives (gemﬁbrozil), and Niacin. In addition, AZT, Cyclosporine,
Chloroquine, and Colchicine are also found to increase the CK’s
(Abdel-Hamid et al., 2008; Baker et al., 2008).
Table 7 | Differential diagnosis of acquired causes of creatine kinase
elevation.
MYOPATHIES
Drug/toxin-induced
Hypothyroidism/hypoparathyroidism
Metabolic myopathies
Inﬂammatory myopathies
NEUROPATHIES
Guillain–Barre syndrome
MOTOR NEURON DISEASES
Amyotrophic lateral sclerosis
Spinal muscular atrophy
Postpolio syndrome
OTHERS
Race
Sex
Surgery
Trauma (needle EMG studies, intramuscular injections)
Viral illness
Medications
Strenuous exercise
“Idiopathic hyperCKemia”
Table 8 | Effect of race and gender on creatine kinase measurements.
Group Gender/race ULN (97.5%; IU/L)
High Black men 520
Intermediate Nonblack men 345
Black women
Low Nonblack women 145
ULN, upper limits of normal.
ROLE OF EMG AND MUSCLE BIOPSY IN SYSTEMIC ILLNESSES
• Nerve conduction studies and EMG examination are an exten-
sion of the neurological examination. The study is individual-
ized based upon the neurological examination and differential
diagnosis, and modiﬁed in real time as the study progresses to
obtain further information. Localization of the disorder is the
remains the major aim. In patients with pure weakness, elec-
trodiagnostic studies can be useful to localize the disorder to
the motor neuron/axon, neuromuscular junction or the muscle.
The pattern of nerve conduction and more importantly EMG
abnormalities usually can differentiate among these possibilities
and help guide subsequent laboratory testing’s. Electrodiagnos-
tic studies are also able to help determine the problem with
sensory, motor or mixed ﬁbers. It is also able to distinguish
axonal versus demyelinating nerve pathology as well as tempo-
ral course of the disease including hyperacute, acute, subacute
as well as chronic.
• Generally muscle biopsy is not required in myopathy associated
with systemic illnesses. Most of the times a diagnosis can be
made based upon – history, examination, blood tests as well as
EMG’s. Genetic testing is mainly reserved for hereditary mus-
cle disorders. Similar to the use of electrophysiological studies,
biopsy results must be interpreted in the light of the clinical
history and other laboratory studies.
• Muscle biopsy should least likely be considered in patients with
normal strength and normal EMG. In one of the studies of
patients with only muscle pain and a normal neurologic exami-
nation, the probability of having deﬁnite muscle pathology was
found to be 2%. It is not recommended to biopsy muscles that
are MRC grade≤ 3 since results likely to show“end-stage”mus-
cle. Last but not the least; avoid muscles that have been studied
by EMGdue to risk of false positive inﬂammatory results (Engel,
1967; Dabby et al., 2006; Filosto et al., 2007).
• Muscle biopsy remains essential to distinguish polymyositis
from dermatomyositis. Given, dermatomyositis is primarily a
B-cell disorder, there is 30% incidence of associated malignan-
cies and therefore it remains practical to do muscle biopsy for
appropriate, diagnosis, management, and counseling. Muscle
biopsy is occasionally required to differentiate CIM from other
myopathies or from critical illness polyneuropathy. It is also
helpful for prognosis as severe cases especially with necrotizing
myopathy are associated with a high mortality rate (Chawla and
Gruener, 2010).
• Viral infections lead the volumes among infectious disorders
and fortunately, the disorders are usually self limited with-
out the need for a muscle biopsy (Kumar et al., 2011). On
the other hand, the clinical and histopathologic features of
HIV-associated myopathy are indistinguishable from those of
idiopathic polymyositis, and the condition is often referred to
as HIV polymyositis. HIV-associated inclusion body myositis
as well as nemaline rod myopathy has been described as well
Given the treatment of HIV polymyositis is similar to that of
idiopathic polymyositis, in view of the increased risk of oppor-
tunistic infections with immunosuppressant’s, muscle biopsy
can sometimes be helpful (Dalakas et al., 2007; de Sanctis et al.,
2008).
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• Several animal parasites including toxoplasma, trypanosome,
cysticerci, and trichinae, may produce a focal or diffuse inﬂam-
matory myopathy known as parasitic polymyositis. Trichinosis
on occasion may mimic mild dermatomyositis and may require
muscle biopsy. Generally bacterial and fungal infections have
other associated local and systemic symptoms that patients
rarely need a muscle biopsy for the diagnosis (Al-Najar et al.,
2010; Kung et al., 2011).
• Therefore, it remains very prudent for a meticulous selection of
patients before performing a muscle biopsy. Although muscle
biopsy remains a useful tool, molecular genetic studies are now
available for non-invasive diagnosis of muscle diseases with a
suspicion of non-systemic or hereditary disorders (Dabby et al.,
2006; Filosto et al., 2007; Jackson, 2008; Nadaj-Pakleza et al.,
2010; Selcen, 2011).
CONCLUSION
The step wise approach to a patient with muscle weakness can
be extremely helpful in narrowing the differential diagnosis with a
myopathy of systemic diseases.Without compromising the patient
care, the bottom line remains in practicing cost effective medicine
to conﬁrm the diagnosis. Recognition is extremely important as
most of these are reversible when diagnosed and managed in a
timely fashion and thus carry a good prognosis.
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